Addison disease
ORPHA:85138DiseaseNot applicableAll ages
Фенотипы (HPO)56
Облигатный (100%)2
HP:0008163Decreased circulating cortisol level
HP:0008207Primary adrenal insufficiency
Очень частый (80–99%)13
HP:0002014Diarrhea
HP:0002017Nausea and vomiting
HP:0002019Constipation
HP:0002027Abdominal pain
HP:0002039Anorexia
HP:0002615Hypotension
HP:0002960Autoimmunity
HP:0003154Increased circulating ACTH level
HP:0012378Fatigue
HP:0000953Hyperpigmentation of the skin
HP:0001324Muscle weakness
HP:0001508Failure to thrive
HP:0001824Weight loss
Частый (30–79%)17
HP:0000127Renal salt wasting
HP:0000848Increased circulating renin level
HP:0001649Tachycardia
HP:0001897Normocytic anemia
HP:0001944Dehydration
HP:0002149Hyperuricemia
HP:0002153Hyperkalemia
HP:0002902Hyponatremia
HP:0004319Decreased circulating aldosterone level
HP:0005976Hyperkalemic metabolic acidosis
HP:0008226Androgen insufficiency
HP:0012364Decreased urinary potassium
HP:0025406Asthenia
HP:0033834Malaise
HP:0034055Anti-side-chain cleavage enzyme antibody positivity
HP:0034061Anti-steroid 17alpha-hydroxylase antibody positivity
HP:0034071Anti-21-hydroxylase antibody positivity
Периодический (5–29%)21
HP:0030083Salt craving
HP:0100651Type I diabetes mellitus
HP:0000823Delayed puberty
HP:0000829Hypoparathyroidism
HP:0000835Adrenal hypoplasia
HP:0000872Hashimoto thyroiditis
HP:0000958Dry skin
HP:0001045Vitiligo
HP:0001250Seizure
HP:0001278Orthostatic hypotension
HP:0001596Alopecia
HP:0001943Hypoglycemia
HP:0002215Sparse axillary hair
HP:0002321Vertigo
HP:0002608Celiac disease
HP:0002829Arthralgia
HP:0003072Hypercalcemia
HP:0006462Generalized bone demineralization
HP:0008209Premature ovarian insufficiency
HP:0010512Adrenal calcification
HP:0030018Decreased female libido
Очень редкий (1–4%)3
HP:0004860Thiamine-responsive megaloblastic anemia
HP:0008720Primary testicular failure
HP:0100522Thymoma
Эпидемиология4
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-5 / 10 000 | 54 | Specific population | Value and class |
| Point prevalence | 1-5 / 10 000 | 12.5 | Europe | Value and class |
| Point prevalence | 1-5 / 10 000 | 14 | Norway | Value and class |
| Point prevalence | 1-9 / 100 000 | 9.3 | United Kingdom | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)